ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

Phase 2

Terminated

Conditions: Stage I Oral Cavity Squamous Cell Carcinoma
Stage II Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: HPPH
Procedure: Therapeutic Conventional Surgery
Other: Laboratory Biomarker Analysis
Drug: Photodynamic Therapy
Other: Quality-of-Life Assessment

First Posted Date: 2017-03-24

Last Posted Date: 2022-06-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03090412

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Rocherster, Rochester, New York, United States

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Biological: Aldesleukin
Drug: Cyclophosphamide
Drug: Decitabine
Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-01-11

Last Posted Date: 2024-03-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT03017131

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism

Not Applicable

Completed

Conditions: Parathyroid Gland Adenoma
Primary Hyperparathyroidism

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Parathyroidectomy

First Posted Date: 2017-01-05

Last Posted Date: 2021-08-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03011736

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Carcinoma

Interventions: Biological: Botulinum Toxin Type A
Other: Quality-of-Life Assessment
Procedure: Esophagectomy

First Posted Date: 2016-11-17

Last Posted Date: 2023-02-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 33

Registration Number: NCT02965976

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Phase 1

Recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
PD-L1 Positive
Recurrent Head and Neck Squamous Cell Carcinoma
Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Advanced Squamous Non-Small Cell Lung Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Biological: Pembrolizumab
Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

First Posted Date: 2016-11-04

Last Posted Date: 2024-08-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 242

Registration Number: NCT02955290

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 2 locations

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2

Completed

Conditions: Ovarian Serous Adenocarcinoma
BRCA1 Gene Mutation
BRCA2 Gene Mutation
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Biological: Durvalumab
Other: Laboratory Biomarker Analysis
Drug: Olaparib
Biological: Tremelimumab

First Posted Date: 2016-11-02

Last Posted Date: 2024-11-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02953457

Locations: 🇺🇸
The Feinstein Institute for Medical Research/Lennox Hill Hospital, New York, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IV Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
EGFR Gene Mutation

Interventions: Other: Laboratory Biomarker Analysis
Biological: Nimotuzumab
Biological: Nivolumab

First Posted Date: 2016-10-27

Last Posted Date: 2023-10-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT02947386

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease
Muscle Weakness

Interventions: Dietary Supplement: Cholecalciferol
Dietary Supplement: Multivitamin
Other: Laboratory Biomarker Analysis
Other: Placebo
Other: Questionnaire Administration

First Posted Date: 2016-08-24

Last Posted Date: 2017-02-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 4

Registration Number: NCT02877641

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

Not Applicable

Completed

Conditions: Stage IIC Skin Melanoma
Stage IIIA Skin Melanoma
Stage IIB Skin Melanoma
Stage IIIB Skin Melanoma
Stage IB Skin Melanoma
Stage IIIC Skin Melanoma
Stage IIA Skin Melanoma

Interventions: Procedure: Diagnostic Microscopy
Drug: Fluorescein Sodium Injection
Other: Laboratory Biomarker Analysis
Procedure: Sentinel Lymph Node Biopsy

First Posted Date: 2016-08-05

Last Posted Date: 2022-08-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02857374

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Clear Cell Adenocarcinoma
Ovarian Mucinous Adenocarcinoma
Primary Peritoneal Serous Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-08-02

Last Posted Date: 2021-10-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02853318

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy